Korro Bio, Inc.
Korro Bio, Inc. (NASDAQ: KRRO) is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines based on RNA editing technology. The company's website is www.korrobio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Korro Bio, Inc. does
In the company’s own words
Korro Bio, Inc. (NASDAQ: KRRO) is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines based on RNA editing technology. The company's website is www.korrobio.com.
Korro Bio was formed through a November 2023 business combination between Frequency Therapeutics, Inc. and privately held Korro Bio Ops, Inc. The company operates a proprietary platform called OPERA (Oligonucleotide Promoted Editing of RNA) that harnesses the body's natural RNA editing process to make precise, transient changes to RNA nucleosides, specifically converting adenosine to inosine edits. This approach differs from DNA editing by offering improved specificity, reduced off-target effects, and the ability to re-dose patients, while leveraging established oligonucleotide manufacturing and delivery technologies.
The company's pipeline includes four wholly-owned programs and up to two programs under a collaboration with Novo Nordisk that entered a 12-month pause in November 2025. The lead program, KRRO-121, targets hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy through enhanced ammonia clearance via glutamine synthetase stabilization. The company anticipates a regulatory filing for KRRO-121 in the second half of 2026. Additional programs include a next-generation GalNAc-conjugated therapy for alpha-1 antitrypsin deficiency with development candidate nomination expected in the second quarter of 2026, a longevity and liver health program targeting AMPKγ1 activation, and an ALS program targeting TDP-43 modification.
Korro Bio's OPERA platform integrates expertise in ADAR biology, oligonucleotide chemistry, machine learning optimization, and established delivery modalities including GalNAc-conjugated delivery for subcutaneous administration. The company leverages precedented regulatory pathways for oligonucleotide medicines and can design and synthesize approximately 1,200 oligonucleotides monthly with up to 6,000 assay data points per target. All programs remain in research or preclinical development stages. The company has cash runway extending into the second half of 2028 to support advancement of its pipeline and achievement of anticipated milestones.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1703647
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Korro Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Korro Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Korro Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Korro Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Korro Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”